A cisplatin SVM generated from 17 bladder cancer cell lines in CancerRxGene resulted in 2 equally accurate signatures (with 11.8% cross-validation misclassification) consisting of either PNKP and PRKCA, or ATP7B, CFLAR, FEN1, MAPK3, NFKB1, and SLC22A11. These gene signatures were not useful for predicting patient outcomes due to the limited size of the training set. This evidence concerns the gene MAPK3 and urinary bladder carcinoma.